Friday, March 20, 2020 11:26:18 AM
Researchers screened more than 8000 drug compounds (Video).
Finding faster. Researchers have used Summit, the world’s most powerful and smartest supercomputer, to identify 77 small-molecule drug compounds that might warrant further study in the fight against the SARS-CoV-2 coronavirus.
"Summit" identifies Ifenprodil as potential Coronavirus Treatment
March 19, 2020 - News Release:
Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus
www.globenewswire.com/news-release/2020/03/19/2003362/0/en/Algernon-to-Support-Planned-Phase-2-Trial-of-Ifenprodil-for-Coronavirus.html
Mark Williams PhD MBA
Chief Science Officer
algernonpharmaceuticals.com/overview-and-history/
THE MAD SCIENTIST
/////AMG
Finding faster. Researchers have used Summit, the world’s most powerful and smartest supercomputer, to identify 77 small-molecule drug compounds that might warrant further study in the fight against the SARS-CoV-2 coronavirus.
"Summit" identifies Ifenprodil as potential Coronavirus Treatment
March 19, 2020 - News Release:
Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus
www.globenewswire.com/news-release/2020/03/19/2003362/0/en/Algernon-to-Support-Planned-Phase-2-Trial-of-Ifenprodil-for-Coronavirus.html
Mark Williams PhD MBA
Chief Science Officer
algernonpharmaceuticals.com/overview-and-history/
The Algernon drug development program was the brainchild of Dr. Mark Williams, the Company’s CSO, whose innovative approach to drug discovery was developed over many years as senior scientist in the drug development industry. The company and its business model is highly capital efficient and strives to deliver maximum shareholder value.
Algernon’s unique approach to drug discovery is based on the concept of drug repurposing. Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life.
THE MAD SCIENTIST
/////AMG
Recent AGNPF News
- Grey Matters Improves Warrant Terms of Private Placement • GlobeNewswire Inc. • 05/25/2026 11:00:00 AM
- Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer’s Clinical Trial at 2nd NovaScan Location Planned for Tampa • GlobeNewswire Inc. • 05/20/2026 11:00:00 AM
- Grey Matters Announces Private Placement • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation • GlobeNewswire Inc. • 04/15/2026 08:01:00 PM
- Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation • GlobeNewswire Inc. • 03/31/2026 11:09:55 PM
- Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers • GlobeNewswire Inc. • 03/25/2026 11:00:00 AM
- Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing • GlobeNewswire Inc. • 12/31/2025 09:01:00 PM
- Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche • GlobeNewswire Inc. • 12/23/2025 09:01:00 PM
- Form D/A - Notice of Exempt Offering of Securities: [Amend] • Edgar (US Regulatory) • 12/09/2025 05:01:20 PM
- Algernon Closes Second Tranche of Private Placement Financing • GlobeNewswire Inc. • 11/29/2025 12:51:39 AM
- Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement • GlobeNewswire Inc. • 11/17/2025 12:00:00 PM
- Algernon Closes First Tranche of its Recently Announced Private Placement Financing • GlobeNewswire Inc. • 11/15/2025 12:55:26 AM
- Algernon Health Announces Private Placement • GlobeNewswire Inc. • 11/06/2025 12:04:28 PM
- Algernon Pharmaceuticals Completes Name Change to Algernon Health • GlobeNewswire Inc. • 10/15/2025 11:00:00 AM
- Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection • GlobeNewswire Inc. • 09/25/2025 11:00:00 AM
- Algernon Announces Preferred Share Class Approved at Annual and Special Meeting • GlobeNewswire Inc. • 09/19/2025 08:39:57 PM
